Needham & Company LLC Reaffirms “Hold” Rating for Axonics (NASDAQ:AXNX)

Needham & Company LLC reaffirmed their hold rating on shares of Axonics (NASDAQ:AXNX) in a research report report published on Friday,Benzinga reports.

Axonics Stock Performance

AXNX stock opened at $70.42 on Friday. The company has a market capitalization of $3.60 billion, a P/E ratio of -586.83 and a beta of 0.82. Axonics has a 52-week low of $49.70 and a 52-week high of $70.75. The business has a 50-day simple moving average of $69.70 and a two-hundred day simple moving average of $68.46.

Insiders Place Their Bets

In other Axonics news, CFO Kari Leigh Keese sold 2,961 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $69.41, for a total value of $205,523.01. Following the completion of the sale, the chief financial officer now directly owns 40,362 shares of the company’s stock, valued at approximately $2,801,526.42. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 1.85% of the company’s stock.

Institutional Trading of Axonics

Large investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC increased its stake in shares of Axonics by 0.9% during the 2nd quarter. AQR Capital Management LLC now owns 18,337 shares of the company’s stock worth $1,233,000 after purchasing an additional 161 shares during the last quarter. Xponance Inc. grew its stake in shares of Axonics by 7.5% during the 2nd quarter. Xponance Inc. now owns 3,231 shares of the company’s stock worth $217,000 after acquiring an additional 225 shares during the period. Headlands Technologies LLC grew its stake in shares of Axonics by 31.1% during the 1st quarter. Headlands Technologies LLC now owns 1,117 shares of the company’s stock worth $77,000 after acquiring an additional 265 shares during the period. Arizona State Retirement System increased its holdings in Axonics by 2.5% in the 2nd quarter. Arizona State Retirement System now owns 14,278 shares of the company’s stock worth $960,000 after acquiring an additional 355 shares during the last quarter. Finally, Swiss National Bank lifted its holdings in Axonics by 0.6% during the first quarter. Swiss National Bank now owns 100,000 shares of the company’s stock valued at $6,897,000 after purchasing an additional 600 shares during the last quarter. Hedge funds and other institutional investors own 99.48% of the company’s stock.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.